Covered recipient · General Payments record
NASER EDDIN M GHARAIBEH
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2019–2025
$1,901.20
- Reported across 79 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $522.83 | 17 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $224.62 | 7 |
| Lilly USA, LLC | $132.00 | 2 |
| Insulet Corporation | $68.37 | 3 |
| Corcept Therapeutics | $38.87 | 2 |
| Amgen Inc. | $35.66 | 2 |
| Abbott Laboratories | $23.31 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.31 | 11/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240994169 | CMS |
| Amgen Inc. | $17.01 | 05/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228499011 | CMS |
| Amgen Inc. | $18.65 | 10/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228499009 | CMS |
| Corcept Therapeutics | $19.73 | 05/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1214176418 | CMS |
| Corcept Therapeutics | $19.14 | 11/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1214176480 | CMS |
| Insulet Corporation | $17.11 | 01/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1207064799 | CMS |
| Insulet Corporation | $25.74 | 05/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1207085445 | CMS |
| Insulet Corporation | $25.52 | 08/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1207108035 | CMS |
| Lilly USA, LLC | $18.04 | 05/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186824056 | CMS |
| Lilly USA, LLC | $113.96 | 11/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186835928 | CMS |
| Novo Nordisk Inc | $14.31 | 01/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188261140 | CMS |
| Novo Nordisk Inc | $9.90 | 02/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189043630 | CMS |
| Novo Nordisk Inc | $22.00 | 02/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188272966 | CMS |
| Novo Nordisk Inc | $124.98 | 05/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188620675 | CMS |
| Novo Nordisk Inc | $17.76 | 09/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189163132 | CMS |
| Novo Nordisk Inc | $17.46 | 09/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188540993 | CMS |
| Novo Nordisk Inc | $18.21 | 11/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189056893 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.